| Literature DB >> 33643908 |
Shengyu Fang1, Ziwen Fan2, Zhiyan Sun1, Yiming Li2, Xing Liu3, Yuchao Liang2, Yukun Liu2, Chunyao Zhou2, Qiang Zhu2, Hong Zhang2, Tianshi Li2, Shaowu Li4, Tao Jiang1,2, Yinyan Wang1,2, Lei Wang2.
Abstract
The detection of mutations in telomerase reverse transcriptase promoter (pTERT) is important since preoperative diagnosis of pTERT status helps with evaluating prognosis and determining the surgical strategy. Here, we aimed to establish a radiomics-based machine-learning algorithm and evaluated its performance with regard to the prediction of mutations in pTERT in patients with World Health Organization (WHO) grade II gliomas. In total, 164 patients with WHO grade II gliomas were enrolled in this retrospective study. We extracted a total of 1,293 radiomics features from multi-parametric magnetic resonance imaging scans. Elastic net (used for feature selection) and support vector machine with linear kernel were applied in nested 10-fold cross-validation loops. The predictive model was evaluated by receiver operating characteristic and precision-recall analyses. We performed an unpaired t-test to compare the posterior predictive probabilities among patients with differing pTERT statuses. We selected 12 valuable radiomics features using nested 10-fold cross-validation loops. The area under the curve (AUC) was 0.8446 (95% confidence interval [CI], 0.7735-0.9065) with an optimal summed value of sensitivity of 0.9355 (95% CI, 0.8802-0.9788) and specificity of 0.6197 (95% CI, 0.5071-0.7371). The overall accuracy was 0.7988 (95% CI, 0.7378-0.8598). The F1-score was 0.8406 (95% CI, 0.7684-0.902) with an optimal precision of 0.7632 (95% CI, 0.6818-0.8364) and recall of 0.9355 (95% CI, 0.8802-0.9788). Posterior probabilities of pTERT mutations were significantly different between patients with wild-type and mutant TERT promoters. Our findings suggest that a radiomics analysis with a machine-learning algorithm can be useful for predicting pTERT status in patients with WHO grade II glioma and may aid in glioma management.Entities:
Keywords: TERT promoter mutation; low-grade glioma; machine-learning; nested cross-validation; radiomics
Year: 2021 PMID: 33643908 PMCID: PMC7905226 DOI: 10.3389/fonc.2020.606741
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244